COMMUNIQUÉS West-GlobeNewswire

-
Privia Health to Report First Quarter 2024 Results on Thursday, May 9
09/04/2024 -
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
09/04/2024 -
Signati™ Medical Enrolls First Patient in Groundbreaking Sealed Vasectomy Procedure Trial
09/04/2024 -
Curium Announces First Commercial Dose in the Netherlands of PYLCLARI® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
09/04/2024 -
Virbac : Declaration of the number of shares and voting rights 03/2024
09/04/2024 -
Virbac : Déclaration d'actions et de droits de vote 03/2024
09/04/2024 -
Nanox Announces Collaboration with AhealthZ and SCL Science to Enter South Korean Market
09/04/2024 -
STRATA Skin Sciences Announces Renewal of Exclusive Distribution Agreements in China and Japan
09/04/2024 -
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
09/04/2024 -
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
09/04/2024 -
Chromocell Issues Letter to Stockholders from Chief Executive Officer
09/04/2024 -
Allogene Therapeutics Announces Q2 Investor Conference Participation
09/04/2024 -
Autonomix Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation
09/04/2024 -
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
09/04/2024 -
Tome Biosciences Announces US Patent Issued for Integrase-Mediated Programmable Genomic Integration
09/04/2024 -
Clearmind Medicine CEO Issues Letter to Shareholders
09/04/2024 -
Mainz Biomed Reports Full Year 2023 Financial Results
09/04/2024 -
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
09/04/2024 -
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
09/04/2024
Pages